<DOC>
	<DOCNO>NCT02552342</DOCNO>
	<brief_summary>The purpose present study ass efficacy methylprednisolone adjuvant therapy patient severe community-acquired pneumonia ( CAP ) ( PSI 4-5 ) . The hypothesis study methylprednisolone decrease mortality severe CAP without significant side effect , reduction time clinical stability failure rate treatment .</brief_summary>
	<brief_title>Corticosteroid Therapy Severe Community-Acquired Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>communityacquired pneumonia PSI score：45 least one follow conditions：①CRP ≥150 mg/L , ②oxygen index ≤250 , ③bilateral multilober infiltrates chest image , ④ area pulmonary infiltrates increase &gt; 50 % 48 hous , ⑤fever high 39℃ exceed 72 hour nosocomial Pneumonia aspiration pneumonia acute burn injury gastrointestinal bleeding within past three month uncontrolled diabetes mellitus pregnant breast feed condition require treatment great 0.5 mg/kg/d prednison equivalent severe immunosuppression ( human immunodeficiency virus infection , immunosuppressive condition medication ) active tuberculosis preexist medical condition life expectancy le 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>